Pioneers in the treatment of
chronic kidney disease
INNOVATION IN CELLULAR AND GENE THERAPY
ProKidney is an advanced biotech company built by innovators who are developing pioneering therapies that will transform the medical landscape and change patients’ lives.
Our technology repairs and restores diseased kidneys using a patient’s own cells and may prevent or delay dialysis or transplant.
We aspire to cure kidney disease, not manage kidney failure.
Recent Events
May 23, 2022, 1:15 pm EDT
Analyst and Investor day April 28, 2022
ProKidney Analyst Day Transcript PDF
ProKidney Analyst Day Slide Deck PDF
ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III
REACT® has received Regenerative Medicine Advanced Therapy (“RMAT”) designation, as well as U.S. FDA and European Medicines Agency guidance, for its Phase 3 clinical program; Phase 3 trial launched in the United States on schedule in January 2022.
Transaction values the combined company at an equity value of $2.64 billion post-money and is expected to provide up to $825 million in gross cash proceeds, including a fully committed PIPE of $575 million, and up to $250 million of cash held in the trust account of Social Capital Suvretta Holdings Corp. III.
PIPE is led by a $125 million investment from Social Capital, with an additional $50 million from ProKidney’s existing investors, approximately $30 million from Suvretta Capital’s Averill strategy and remaining $370 million from institutional investors and family offices.
Proceeds will fund REACT®’s Phase 3 development program, accelerate manufacturing buildout, and ultimately prepare for its global commercial launch.
Research Article – Advances in CKD 2021
Advanced cell therapies with autologous, homologous cells show promise to effect reparative and restorative changes in the chronic kidney disease (CKD) nephron. We present our protocol and preliminary analysis of an IRB-approved, phase I single-group, open-label trial that tests the safety and efficacy of Renal Autologous Cell Therapy (REACT; NCT 04115345) in adults with congenital anomalies of the kidney and urinary tract (CAKUT).
